A single dose, randomized, blinded, bioequivalence study of desvenlafaxine extended release tablets in a 2 way crossover comparison against the innovator desvenlafaxine extended release tablet conducted under fasting conditions in healthy male and female volunteers

Trial Profile

A single dose, randomized, blinded, bioequivalence study of desvenlafaxine extended release tablets in a 2 way crossover comparison against the innovator desvenlafaxine extended release tablet conducted under fasting conditions in healthy male and female volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Major depressive disorder; Vasomotor symptoms
  • Focus Pharmacokinetics
  • Sponsors Zenith Technology Corporation
  • Most Recent Events

    • 27 Aug 2014 Status changed from not yet recruiting to completed, as per Australian New Zealand Clinical Trials Registry record.
    • 28 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top